Baird Medical Investment (NASDAQ:BDMD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Baird Medical Investment (NASDAQ:BDMD) from a sell rating to a hold rating in a report released on Saturday morning.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Baird Medical Investment in a research note on Thursday, October 30th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Baird Medical Investment has an average rating of “Sell”.

Baird Medical Investment Trading Down 3.6%

Shares of Baird Medical Investment stock opened at $1.35 on Friday. Baird Medical Investment has a one year low of $1.02 and a one year high of $12.50. The stock has a 50 day moving average price of $1.43 and a 200-day moving average price of $2.54.

Institutional Trading of Baird Medical Investment

Institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC acquired a new position in shares of Baird Medical Investment during the third quarter worth $99,000. Jane Street Group LLC acquired a new position in shares of Baird Medical Investment in the 2nd quarter valued at $142,000. Finally, Geode Capital Management LLC raised its stake in Baird Medical Investment by 59.7% during the 2nd quarter. Geode Capital Management LLC now owns 25,442 shares of the company’s stock worth $93,000 after acquiring an additional 9,511 shares in the last quarter. 19.78% of the stock is currently owned by hedge funds and other institutional investors.

Baird Medical Investment Company Profile

Baird Medical Investment Holdings Ltd. is a medical technology company, which engages in the development and provision of medical devices. It is also involved in the design, development, manufacturing, and sale of microwave ablation medical devices, as well as sale of other medical devices. The company was founded on June 16, 2023 and is headquartered in Guangzhou, China.